Teva Pharmaceutical Industries Ltd (ADR) Stock Nasdaq
Stocks
US8816242098
Pharmaceuticals
OTC Markets Traded| Market Cap | 43.66B 37.37B 34.93B 32.02B 60.18B 4,178B 61.37B 414B 161B 2,093B 164B 160B 6,941B | P/E 2026 * |
49.4x | P/E 2027 * | 20.2x |
|---|---|---|---|---|---|
| Enterprise Value | 55.54B 47.54B 44.43B 40.73B 76.55B 5,315B 78.06B 526B 205B 2,662B 209B 204B 8,829B | EV / Sales 2026 * |
3.35x | EV / Sales 2027 * | 3.02x |
| Free-Float |
88.59% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Teva Pharmaceutical Industries Ltd (ADR)
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 57 | 2022-12-31 |
Eli Kalif
DFI | Director of Finance/CFO | 53 | 2019-12-21 |
Matthew Shields
COO | Chief Operating Officer | 52 | 2024-06-02 |
| Director | Title | Age | Since |
|---|---|---|---|
Amir Elstein
BRD | Director/Board Member | 69 | 2008-12-31 |
Sol Barer
CHM | Chairman | 78 | 2017-02-05 |
Rosemary Crane
BRD | Director/Board Member | 65 | 2015-08-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 43.66B | |
| -2.81% | +1.98% | +76.96% | +127.73% | 1,141B | |
| -2.21% | +2.50% | +50.38% | +55.01% | 659B | |
| -1.56% | +5.25% | +26.98% | +74.39% | 470B | |
| +1.20% | +1.72% | +42.89% | +45.78% | 366B | |
| -0.61% | +1.72% | +25.21% | +41.34% | 302B | |
| +0.32% | +3.30% | +2.60% | +13.42% | 254B | |
| -1.95% | +4.22% | +46.75% | +65.66% | 239B | |
| -1.10% | -1.12% | -14.91% | -52.66% | 207B | |
| -2.82% | +5.57% | +21.58% | +89.04% | 183B | |
| Average | -0.48% | +4.10% | +30.94% | +51.08% | 424.55B | |
| Weighted average by Cap. | -0.06% | +4.31% | +44.42% | +70.86% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 16.58B 14.19B 13.26B 12.16B 22.85B 1,587B 23.31B 157B 61.23B 795B 62.26B 60.9B 2,636B | 17.3B 14.81B 13.84B 12.69B 23.85B 1,656B 24.32B 164B 63.89B 829B 64.97B 63.56B 2,751B |
| Net income | 1.14B 976M 912M 836M 1.57B 109B 1.6B 10.81B 4.21B 54.66B 4.28B 4.19B 181B | 2.34B 2B 1.87B 1.71B 3.22B 224B 3.28B 22.15B 8.63B 112B 8.77B 8.58B 371B |
| Net Debt | 11.88B 10.17B 9.5B 8.71B 16.37B 1,137B 16.69B 113B 43.86B 569B 44.6B 43.62B 1,888B | 8.61B 7.37B 6.89B 6.32B 11.87B 824B 12.1B 81.6B 31.79B 413B 32.33B 31.63B 1,369B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
